D-0502

DRUG5 trials

Sponsors

InventisBio Co., Ltd, Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions

Breast CancerHealthy Female VolunteerLocally Advanced Breast Cancer (LABC)Metastatic Breast Cancer

Phase 1

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

CompletedNCT03471663

InventisBio Co., LtdBreast Cancer

Start: 2018-03-18End: 2023-10-18Updated: 2024-01-08

Food Effect Study of D-0502 Tablet in Healthy Volunteers

CompletedNCT03810625

InventisBio Co., LtdBreast Cancer

Start: 2018-10-23End: 2019-04-17Updated: 2019-08-07

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

CompletedNCT05226338

InventisBio Co., LtdHealthy Female Volunteer

Start: 2021-10-27End: 2022-05-11Updated: 2022-08-08

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Not yet recruitingNCT07336771

Jiangsu Alphamab Biopharmaceuticals Co., LtdLocally Advanced Breast Cancer (LABC), Metastatic Breast Cancer

Start: 2026-01-31End: 2028-06-30Target: 60Updated: 2026-01-13

Phase 3

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

RecruitingNCT06954961

InventisBio Co., LtdBreast Cancer

Start: 2022-09-15End: 2028-12-31Target: 640Updated: 2026-03-31

Related Papers

Abstract PS15-02: A Phase Ⅰb Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

Cancer Research2024-05-021 citations

Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer

Cancer Research2021-02-1520 citations

Abstract OT1-01-04: Phase 1 study of D-0502, an orally bioavailable SERD with optimized pharmacological and PK/PD property for ER-positive breast cancer

Cancer Research2019-02-151 citations